Department of Pharmacology, UIHC Center for Hypertension Research, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Department of Physiology, Cardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
J Clin Invest. 2019 Mar 21;129(6):2318-2332. doi: 10.1172/JCI123462.
Mice selectively expressing PPARγ dominant negative mutation in vascular smooth muscle exhibit RhoBTB1-deficiency and hypertension. Our rationale was to employ genetic complementation to uncover the mechanism of action of RhoBTB1 in vascular smooth muscle. Inducible smooth muscle-specific restoration of RhoBTB1 fully corrected the hypertension and arterial stiffness by improving vasodilator function. Notably, the cardiovascular protection occurred despite preservation of increased agonist-mediated contraction and RhoA/Rho kinase activity, suggesting RhoBTB1 selectively controls vasodilation. RhoBTB1 augmented the cGMP response to nitric oxide by restraining the activity of phosphodiesterase 5 (PDE5) by acting as a substrate adaptor delivering PDE5 to the Cullin-3 E3 Ring ubiquitin ligase complex for ubiquitination inhibiting PDE5. Angiotensin-II infusion also caused RhoBTB1-deficiency and hypertension which was prevented by smooth muscle specific RhoBTB1 restoration. We conclude that RhoBTB1 protected from hypertension, vascular smooth muscle dysfunction, and arterial stiffness in at least two models of hypertension.
血管平滑肌中选择性表达 PPARγ 显性负突变的小鼠表现出 RhoBTB1 缺乏和高血压。我们的基本原理是利用基因互补来揭示 RhoBTB1 在血管平滑肌中的作用机制。诱导性平滑肌特异性恢复 RhoBTB1 完全纠正了高血压和动脉僵硬,改善了血管舒张功能。值得注意的是,尽管保留了增加的激动剂介导的收缩和 RhoA/Rho 激酶活性,心血管保护仍然发生,这表明 RhoBTB1 选择性地控制血管舒张。RhoBTB1 通过充当将 PDE5 递送至 Cullin-3 E3 环泛素连接酶复合物进行泛素化抑制 PDE5 的底物衔接子,增强了对一氧化氮的 cGMP 反应,抑制了磷酸二酯酶 5(PDE5)的活性。血管紧张素-II 输注也导致 RhoBTB1 缺乏和高血压,而平滑肌特异性 RhoBTB1 恢复可预防这种情况。我们得出结论,RhoBTB1 在至少两种高血压模型中可预防高血压、血管平滑肌功能障碍和动脉僵硬。